CDK4 Genotype

Melanoma that appears before 40, keeps coming back, or clusters across close relatives is not always bad luck. In a small number of families, a single inherited gene change drives that pattern, and this test can find it.

Knowing whether you carry this variant changes how closely your skin, and your relatives' skin, should be watched. It is a once-in-a-lifetime answer that can reshape decades of surveillance.

What This Gene Does

CDK4 (cyclin-dependent kinase 4) is a protein that acts like an accelerator for cell division, pushing cells from a resting state into copying their DNA. A built-in brake protein normally clamps onto it to slow things down.

The high-risk inherited variants sit at a single spot in the gene called codon 24 (one position in the DNA code) and swap one building block, producing versions known as R24H or R24C. These changes stop the brake from gripping, so the accelerator stays pressed and cells divide more freely. This test reads the DNA you were born with and reports whether one of these variants is present.

Melanoma Risk

The inherited high-risk form of this gene is one of the strongest known drivers of melanoma that runs in families. In studied carrier families, most people who inherited the variant developed melanoma, and estimates of how many do so by age 50 have ranged from roughly two-thirds to about three-quarters. These figures come from families already selected for heavy melanoma burden, so they likely overstate the risk for a carrier identified in other circumstances, and published penetrance estimates vary between studies.

Melanoma also tended to appear young. The median age at first diagnosis was 39 years, roughly 15 years earlier than in the general white population, and a meaningful share of carriers were diagnosed before age 30. If you carry this variant, the practical message is that vigilance needs to start early and never really stop.

More Than One Melanoma

Carriers frequently develop several separate melanomas over a lifetime, not just one. In the largest family series, 41.7% of affected carriers developed multiple primary melanomas. Carriers were also more likely to have many clinically unusual moles (called atypical nevi), which is part of why lifelong skin monitoring matters so much for this group.

Inherited risk can stack. Among carriers, red-hair pigment gene variants (in a gene called MC1R) were more common in those who developed multiple melanomas, suggesting other inherited factors can amplify the danger already carried by this gene.

Some hereditary melanoma families also show raised rates of other cancers, particularly pancreatic and breast cancer. Most of that evidence comes from families carrying the more common CDKN2A change rather than this gene, so whether CDK4 carriers share the same added risk is not well established. It is still worth discussing your full family cancer history with a specialist.

Where Tumors Tend to Appear

One smaller family study found that 87% of melanomas in carriers appeared away from the trunk, on sites such as the head, neck, arms, or legs. That result came from just 15 patients, so it points to a possible pattern rather than a firm rule. It is a reason to check all skin surfaces carefully, not just the areas people usually worry about.

How This Differs From the More Common Melanoma Gene

Most inherited melanoma that gets a genetic explanation traces to a different gene, CDKN2A, not this one. The two produce families that look almost identical, with similar ages at diagnosis and similar melanoma counts, so family history alone cannot separate them.

The high-risk variants tested here are far rarer. Several national studies of melanoma-prone families found no CDK4 mutations at all. Because of this, this gene is usually tested after a CDKN2A result comes back negative, as part of a broader hereditary melanoma workup rather than as a first step.

Your Result Does Not Change

This is a germline test, meaning it reads the DNA you were born with. The answer is permanent and does not need to be repeated. Its value comes not from retesting but from what you do with the result over the following decades.

If you carry the high-risk variant, the thing to track over time is not the gene but your skin. Most carrier families move to regular full-skin dermatology exams, often starting in adolescence or early adulthood and continuing for life. A one-time genetic answer sets the schedule for a lifetime of surveillance.

If You Carry the Variant

A positive result is a starting point for action, not a diagnosis. The pathway forward depends on combining the genetic finding with your personal and family history, and a few steps consistently make sense:

• Confirm and counsel: a genetic counselor can confirm the finding and place it in the context of your full family history.
• Set up surveillance: a dermatologist experienced with high-risk patients can establish a schedule of full-skin exams and teach thorough self-checks.
• Test relatives: because this is inherited, first-degree relatives (children, siblings, parents) each have a meaningful chance of carrying the same variant and may benefit from their own test.
• Widen the net if negative: if your melanoma family history is strong but this test is negative, a broader multigene melanoma panel (including CDKN2A and other genes) is the logical next move.

What This Test Can and Cannot Tell You

A genetic result is only as informative as the variants the test is designed to detect and the family context around it. A few limits are worth keeping in mind:

• Panel coverage: this test looks for specific known CDK4 variants. A negative result means those variants were not found, not that every possible change in the gene has been ruled out.
• Ancestry and family history: these variants are rare everywhere and have been described in only a small number of families worldwide, so interpretation depends heavily on your background and how strong your family history is.
• Uncertain variants: occasionally a gene change of unclear meaning turns up. This is not a clear yes or no and needs expert interpretation rather than assuming the worst.
• Consumer reports are not equivalent: ancestry-style consumer genetic reports generally do not cover these rare disease-causing variants, so a clean consumer report is not reassurance here.